Connect with us

News Wire

‘Made in India – The story of Desh Bandhu Gupta, Lupin and Indian Pharma’ Book Launched in Mumbai

MUMBAI, India, Feb. 9, 2026 /PRNewswire/ — Made in India, written by Sundeep Khanna and Manish Sabharwal, traces three remarkable journeys: the rise of India’s pharma industry, the birth and evolution of Lupin (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and the extraordinary life of its founder, Desh Bandhu Gupta. Together, the three journeys illuminate how a country once completely dependent on imported medicines became the world’s pharmacy. The book shares how an individual’s life, shaped early by adversity, growing up without privilege or patronage, unpredictably nurtured hunger and drive, to navigate an unforgiving state, blend national health priorities and global standards, to build a multibillion-dollar enterprise whose medicines reach patients in over 120 countries.

Made in India shows the distance travelled by a village boy from Rajasthan, who went on to become a teacher, professor and pharmaceutical employee, before founding a company worth $10 billion. It is the story of how an unlikely entrepreneur, given his role models, fought the system and left teaching and pharma jobs, going on to build a successful company, giving wings to a world-class industry and became a business icon for a nation.

Written with candor by TeamLease Services co-founder Manish Sabharwal and journalist Sundeep Khanna, the book confronts failures, financial crises, and the personal toll of leadership, alongside achievement and success, in the building of one of the world’s biggest generics firms. This is a riveting portrait of entrepreneurship without mythmaking – of how institutions are built slowly, tested severely and rebuilt with resolve. Made in India weaves vivid anecdotes tracing Desh Bandhu Gupta’s transformation from a humble professor to a pharma titan, finding his true calling in tending to the unmet needs of people. It issues a powerful call to future leaders, showcasing his journey of visionary entrepreneurship: rising from setbacks with raw grit and unshakeable conviction. 

Made in India also spotlights Desh Bandhu Gupta’s wife Manju Gupta’s pivotal role amid the trials and triumphs of building Lupin. Together, the couple also built community service and rural support programs, even as Lupin and India became a reliable global supplier of pharmaceuticals.

India has today become the world’s pharmacy: Nearly half of the 400 billion pills Americans consume every year are made in India, as are 60 per cent of the world’s vaccines. Of the 700 US Food and Drug Administration-approved factories that sell medicines in the US, a third are located in India. The co-creators of Indian pharma – Dr. Yusuf Hamied (Cipla), Anji Reddy (Dr. Reddy’s), Parvinder Singh (Ranbaxy), Dilip Shanghvi (Sun), Ramanbhai Patel (Zydus-Cadila), Habil Khorakiwala (Wockhardt) and DBG (Lupin) – matter more to India than their companies’ revenues, exports or profits because they saw something no one else did. Together, they raised India’s soft and hard power, demolished the myth that multinationals possess unfair advantages over Indian companies, and ended pessimism about India’s ability to export goods, making pharma India’s biggest manufacturing success. Together, they showed the world that a developing nation can dominate a complex industry when brilliant entrepreneurs meet smart policy. Together, they made India ‘Pharmacy to the world’.

Made in India came alive during the launch as the authors, and the publisher shared their journeys, followed by a rich and engaging panel discussion on ‘Past and Future of Indian Pharma’ with pharma leaders Dilip Shanghvi, Sun Pharma, Dr. Yusuf Hamied, Cipla, G.V. Prasad, Dr. Reddy’s, Vinita Gupta, Lupin, and Prof. M. M. Sharma, Ex-(UDCT) ICT. The panel discussed insights on leadership, nation-building, and the Indian pharma industry’s crucial role in making healthcare affordable and accessible globally. 

Praise for the book:

Dilip Sanghvi of Sun Pharma said, “DBG was a visionary whose heart beat for India and for Indian patients. His relentless focus on excellence defined his personality. He was a remarkable role model for all of us and one of the true architects who helped shape India’s journey to becoming the pharmacy to the world”.

Yusuf Hamied of Cipla said, “DBG built Lupin from extremely modest beginnings, guided by determination and a deep commitment to serving patients. DBG’s life story is not only inspiring, but also a reminder of how one individuals purpose can make healthcare accessible and affordable across the world”.

Made in India is a book for everyone thinking about India’s place in the world, seeking role models of a world leading industry from India, entrepreneurs and business people looking for inspiration about building a valuable company, and finally, India’s young and their parents, aiming to build ambition, exploration and determination. 

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 120 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Lupin Human Welfare and Research Foundation has impacted more than 2.02 million beneficiaries across 5400 villages in 26 districts, spread across eight states in India.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin 

Photo: https://oyefilmy.com/wp-content/uploads/2026/02/made-in-india-the-story-of-desh-bandhu-gupta-lupin-and-indian-pharma-book-launched-in-mumbai-1.jpg

Photo: https://oyefilmy.com/wp-content/uploads/2026/02/made-in-india-the-story-of-desh-bandhu-gupta-lupin-and-indian-pharma-book-launched-in-mumbai-2.jpg

Logo: https://oyefilmy.com/wp-content/uploads/2026/02/made-in-india-the-story-of-desh-bandhu-gupta-lupin-and-indian-pharma-book-launched-in-mumbai-3.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/made-in-india–the-story-of-desh-bandhu-gupta-lupin-and-indian-pharma-book-launched-in-mumbai-302682480.html

Continue Reading
Advertisement
Click to comment

You must be logged in to post a comment Login

Leave a Reply

News Wire

Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network

MUMBAI, India, March 11, 2026 /PRNewswire/ — Reliance Digital announces the offline retail availability of iQOO, the high-performance smartphone brand built for today’s youth and tech-forward consumers. Following strong traction in online channels, iQOO is now extending its presence into physical retail, allowing customers to experience and purchase its devices first-hand at Reliance Digital stores across India.

Known for pushing the boundaries of speed, and power, the iQOO 15R is powered by the Snapdragon 8 Gen 5, delivering exceptional speed, responsiveness, and sustained performance throughout the day. It packs iQOO’s biggest battery yet in an ultra-slim 7.90mm design, making it India’s slimmest smartphone with a 7600 mAh battery.

The device features a 6.5K IceCore VC Cooling Chamber for stable performance and runs on OriginOS 6.0 based on Android 16 out of the box, supported by 4 years of software updates and 6 years of security updates. It is also equipped with a Sony LYT-700V OIS camera, a 1.5K 144Hz AMOLED EyeCare display, and IP68 & IP69 dust and water resistance, making it a dependable daily partner for professionals on the go.

The brand’s offline expansion marks an important step in deepening consumer engagement by offering hands-on access to its devices, enabling customers to explore iQOO’s powerful performance, advanced display technology, and flagship-grade camera capabilities in a real-world retail environment.

The availability of iQOO at Reliance Digital brings together two brands driven by innovation and consumer experience. While iQOO continues to build its reputation as a performance-led smartphone brand, Reliance Digital strengthens its portfolio by offering customers access to cutting-edge technology brands through its extensive nationwide retail network.

Through engaging in-store experiences, knowledgeable staff, and immersive product demonstrations, Reliance Digital aims to help consumers better understand iQOO’s performance-first DNA. This move further reinforces Reliance Digital’s commitment to staying ahead of evolving consumer preferences and serving as a preferred destination for discovering new-age technology.

With this expansion, Reliance Digital continues to play a key role in shaping India’s consumer electronics landscape by bringing future-ready brands closer to customers, while enabling smartphone brands like iQOO to build stronger connections with a growing, performance-driven audience.

The all new iQOO 15R is now available at Reliance Digital stores nationwide.

Photo: https://oyefilmy.com/wp-content/uploads/2026/03/reliance-digital-introduces-high-performance-iqoo-15r-to-its-nationwide-store-network-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/reliance-digital-introduces-high-performance-iqoo-15r-to-its-nationwide-store-network-302711079.html

Continue Reading

News Wire

Kotak Alts announces winner of the inaugural Katalyst Awards

Ms Himani Choudhary named Katalyst for the year – India’s Best Financial Content Creator; wins Rs. 25 Lakhs

MUMBAI, India, March 10, 2026 /PRNewswire/ — Kotak Katalyst Awards, a national initiative instituted to recognise excellence and responsibility in financial content creation has announced the winner of its first Katalyst edition. Kotak Alternate Asset Managers Limited (“Kotak Alts”) today announced Himani Choudhary as the winner. The winner was awarded a prize of INR 25 Lakhs, positioning Katalyst among the most meaningful recognitions for financial content creators in India.

Srini Sriniwasan, Managing Director, Kotak Alts, said, “The Kotak Alts Katalyst Awards were instituted to recognize content creators who are contributing meaningfully to financial literacy in India. As investor participation deepens, audiences are seeking clarity, context, and credibility. The response from creators was overwhelming and points to the new generation of financial educators.  As the inaugural winner Ms. Himani Chaudhary, exemplifies the standard of financial communication that Katalyst seeks to encourage.”

The first edition of the Kotak Alts Katalyst Awards received over six hundred entries from across 19 states and in 8 languages, reflecting the growing role of digital creators in shaping financial awareness. Conceived in response to increasing clutter and misinformation in the financial ecosystem, Katalyst is designed to recognize creators who place accuracy, transparency, and investor interest at the core of their work.

The winning content, ‘Personal Finance & Major Finance Updates’ by Himani Choudhary, was recognised for its clarity, originality, and credibility. The jury noted the content’s ability to explain complex financial concepts in a clear and measured manner, supported by strong research and a consistent focus on investor education over virality.

To ensure a robust and transparent evaluation process, the awards framework was designed and audited by EY. The top thirty entries were assessed by an academic jury.

The top 10 finalists were subsequently evaluated by a grand jury comprising Kunal Shah, Founder and CEO of CRED; Radhika Gupta, Managing Director and CEO of Edelweiss Mutual Fund; and Alpesh Shah, Managing Director and Senior Partner at Boston Consulting Group, and chaired by Ananth Narayan, former Whole–Time Member of SEBI with extensive capital markets and regulatory experience.

The Katalyst Awards recognise financial content creators who priorities financial literacy, substance, and long–term investor interest. Through this initiative, Kotak Alts aims to encourage responsible financial communication and support the development of informed and confident investors across India.

About Kotak Alternate Asset Managers Ltd: Kotak Alternate Asset Managers Limited (‘Kotak Alts’), a part of Kotak Mahindra Group (‘Kotak’), focuses on Alternate Asset Management and Investment Advisory businesses. Kotak Alts was set up in early 2005 and has raised, managed, and advised over USD 22 billion across different asset classes, including Private Equity, Real Estate, Infrastructure, Special Situations, Private Credit, and Investment Advisory. The asset management business and investment advisory vertical are managed by independent specialist teams. For more information, visit https://www.kotakalternateasset.com/

Image: https://oyefilmy.com/wp-content/uploads/2026/03/kotak-alts-announces-winner-of-the-inaugural-katalyst-awards-1.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/kotak-alts-announces-winner-of-the-inaugural-katalyst-awards-302709187.html

Continue Reading

News Wire

Paperpal for Life Sciences Establishes HIPAA Readiness, Strengthening Enterprise Adoption of AI in Regulated Medical and Scientific Writing Workflows

MUMBAI, India, March 10, 2026 /PRNewswire/ — Paperpal for Life Sciences, an enterprise-grade Artificial Intelligence (AI) platform by Cactus Communications, purpose-built for Medical Affairs and Life Sciences organizations, announced the completion of an assessment evaluating its operational and technical safeguards to support Health Insurance Portability and Accountability Act (HIPAA) requirements. This milestone reinforces Paperpal’s commitment to meeting the rigorous standards of security, data protection, and regulatory readiness required for regulated scientific workflows.

Growing AI use in medical affairs writing and publication workflows is intensifying scrutiny on data privacy, governance, and regulatory accountability. To support these evolving needs, Paperpal for Life Sciences has undertaken an assessment of its systems and processes to evaluate readiness to support HIPAA compliance, where applicable, and now proudly offers the option to execute a Business Associate Agreement (BAA) for Protected Health Information (PHI) and Personally Identifiable Information (PII). This offering gives customers the confidence that PHI or PII, if received, is handled securely and responsibly, in line with regulatory expectations and enterprise risk management practices.

Paperpal for Life Sciences provides AI writing, literature search, source-grounded summarization with citation support, and critical publication checks, powering medical affairs content creation under stringent data privacy and governance controls. The platform accelerates research-to-publication timelines by upto 25%, supporting faster dissemination of clinical evidence and earlier commercialization of new drugs and therapies.

Nishchay Shah, Group CTO and EVP, Products and AI at Cactus Communications, said, “As AI becomes foundational to regulated scientific and medical workflows, compliance and trust are no longer optional. Paperpal for Life Sciences’ HIPAA readiness measures reflect our secure-by-design approach to AI, strong data governance framework, and alignment with real-world enterprise and regulatory requirements. This milestone enables organizations to adopt AI at scale with confidence that their data, processes, and compliance obligations are protected .”

Elvira Dsouza, President, Cactus Life Sciences, added, “Medical Affairs and Life Sciences teams operate in highly regulated environments where scientific rigor, data privacy, and compliance are non-negotiable. HIPAA readiness positions Paperpal for Life Sciences as a trusted AI partner, one that enables organizations to accelerate evidence generation and scientific communication without compromising regulatory integrity .”

With this announcement, Paperpal for Life Sciences reinforces its position as a purpose-built, enterprise-ready AI platform for medical affairs content generation that supports innovation while meeting the highest standards of privacy, ethics, and regulatory compliance.

Media Contact:

Nidhi Amin

nidhi.amin@cactusglobal.com 

Logo: https://oyefilmy.com/wp-content/uploads/2026/03/paperpal-for-life-sciences-establishes-hipaa-readiness-strengthening-enterprise-adoption-of-ai-in-regulated-medical-and-scientific-writing-workflows-1.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/paperpal-for-life-sciences-establishes-hipaa-readiness-strengthening-enterprise-adoption-of-ai-in-regulated-medical-and-scientific-writing-workflows-302708082.html

Continue Reading

Trending